Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIR: Buloxibutid (C21) in Idiopathic Pulmonary Fibrosis
NCT04533022Phase 2Completed
- Sponsor
- Vicore Pharma
- Start
- Nov 2020
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of buloxibutid in idiopathic pulmonary fibrosis (IPF), sponsored by Vicore Pharma. Primary endpoint: Number of Participants With Adverse Events Occurring Over the Trial Period at 36 weeks. Started Nov 2020; status: completed.
02
Drugs
buloxibutid
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04533022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04533022.